Therapeutic Targets for High Cardiovascular Risk Patients

Risk Stratification and LDL-C Goals

The European Society of Cardiology recommends an LDL-C target of <1.4 mmol/L (<55 mg/dL) with at least a 50% reduction from baseline for patients at very high cardiovascular risk 1
Very high-risk patients, including those with established cardiovascular disease, diabetes with target organ damage, or severe chronic kidney disease, should aim for an LDL-C target <1.4 mmol/L (<55 mg/dL) and ≥50% reduction from baseline 1, 2
For patients with triglycerides ≥200 mg/dL, non-HDL-C becomes a secondary target with a goal of <2.2 mmol/L (<85 mg/dL) 1
High-risk patients should aim for an LDL-C target <1.8 mmol/L (<70 mg/dL) and ≥50% reduction from baseline 1
The American College of Cardiology recommends an LDL-C target <2.6 mmol/L (<100 mg/dL) for moderately high-risk patients, with an optional more aggressive target of <1.8 mmol/L (<70 mg/dL) 3, 4

Statins are the first-choice lipid-lowering treatment for all risk categories, with the goal of achieving at least a 30-40% reduction in LDL-C levels 1, 4, 5
Combination therapy with ezetimibe is recommended if LDL-C goals are not achieved with maximum tolerated statin dose 1
For very high-risk patients not reaching goals on statin plus ezetimibe, adding a PCSK9 inhibitor should be considered 1

When triglycerides are ≥200 mg/dL, non-HDL-C becomes a secondary target of therapy, with a goal 30 mg/dL higher than the identified LDL-C goal 4, 5
The American College of Cardiology recommends considering combination therapy with a fibrate or nicotinic acid for patients with high triglycerides and low HDL-C 3, 4

Patients with type 2 diabetes and cardiovascular disease or chronic kidney disease should aim for LDL-C <1.4 mmol/L (<55 mg/dL) 1
The American College of Cardiology recommends secondary goals of non-HDL-C <2.2 mmol/L (<85 mg/dL) for patients with type 2 diabetes 1
Older adults with established cardiovascular disease should be treated with statins in the same way as younger patients 2, 4, 8

Regular lipid assessments should be performed to monitor treatment efficacy, with more frequent monitoring recommended for patients on lipid-lowering therapy 2, 6
The American College of Cardiology recommends annual monitoring once target is reached 6

Every 1.0 mmol/L reduction in LDL-C is associated with a 20-25% reduction in cardiovascular events 6
Therapeutic lifestyle changes remain essential regardless of pharmacological therapy 4, 5